Prosecution Insights
Last updated: April 19, 2026
Application No. 17/776,961

SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS

Non-Final OA §102
Filed
May 13, 2022
Examiner
ELENISTE, PIERRE PAUL
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Broad Institute Inc.
OA Round
1 (Non-Final)
39%
Grant Probability
At Risk
1-2
OA Rounds
3y 6m
To Grant
71%
With Interview

Examiner Intelligence

Grants only 39% of cases
39%
Career Allow Rate
27 granted / 69 resolved
-20.9% vs TC avg
Strong +32% interview lift
Without
With
+31.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
53 currently pending
Career history
122
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
48.9%
+8.9% vs TC avg
§102
16.5%
-23.5% vs TC avg
§112
20.8%
-19.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 69 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election with traverse of Group I (drawn to a compound/pharmaceutical composition) in the reply filed on 03/19/2025 is acknowledged. Claims 1, 3-6, 11-12, 15-24 are pending of which claim 15-19, 21-24 in Group II, is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected INVENTION, there being no allowable generic or linking claim. The restriction requirement is still deemed proper and is made Final. Pending claims 1, 3-6, 11-12 and 20 have been examined on the merits. Please note, for clarity of the record, Applicant ’s election of compound ETP-47037 PNG media_image1.png 120 260 media_image1.png Greyscale Please also note in the interest of compact prosecution, that during the course of examination any prior art identified that relates to non-elected subject matter is applied to demonstrate the non-allowability of the generic claims and/or as discussed below. Claim Rejections – 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by CAS Registry Number 2224237-28-7 (20 May 2018). CAS RN 2224268-91-9 discloses the following compound as part of a chemical library on or about 20 May 2018. PNG media_image2.png 255 518 media_image2.png Greyscale This compound meets each and every chemical structure variable as listed in the instant claims, wherein R1 is PNG media_image3.png 191 192 media_image3.png Greyscale substituted with a methyl group; R2 is hydrogen; and A is PNG media_image4.png 123 108 media_image4.png Greyscale ; Z is PNG media_image5.png 153 153 media_image5.png Greyscale . The compound disclosed also anticipates the claimed composition. Therefore, claim 1 is anticipated. Claim Objections Claims 3-6, 11-12 and 20 are objected to for depending from a rejected base claim. Subject Matter Free of the Art of Record The subject matter of claims 3-6, 11-12, and 20 are free of the art of record. The closest prior art are the CAS abstracts. While CAS RN 2224268-91-9 teaches a compound of formula I, there is no motivation for a person of ordinary skill in the art to modify the teaching of CAS RN 2224268-91-9 to arrive at the claimed compound. These claims are not allowable until the objection is overcome. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to PIERRE PAUL ELENISTE whose telephone number is (571)270-0589. The examiner can normally be reached Monday - Friday 8:00 am - 5:00 pm (EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JAMES H ALSTRUM-ACEVEDO can be reached at (571) 272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /P.P.E./Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

May 13, 2022
Application Filed
Oct 16, 2025
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12590099
INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION
2y 5m to grant Granted Mar 31, 2026
Patent 12590057
CRYSTALLINE COMPLEXES
2y 5m to grant Granted Mar 31, 2026
Patent 12583873
AMINO ACID MINERAL COMPLEX HAVING IMMUNOPOTENTIATING ACTIVITY AND COMPOSITION FOR FOODS, PHARMACEUTICALS, OR FEEDS COMPRISING SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12545672
ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF
2y 5m to grant Granted Feb 10, 2026
Patent 12545639
3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
39%
Grant Probability
71%
With Interview (+31.6%)
3y 6m
Median Time to Grant
Low
PTA Risk
Based on 69 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month